N. (Nick) Beije, MD, PhD

Clinical Focus

My clinic specializes in the treatment of patients with genitourinary malignancies, with a particular focus on prostate cancer. I am a strong advocate for clinical trial participation, seeing it as essential to advancing personalized care and improving outcomes for future patients. 

 

Research Program

My research encompassed two primary lines associated with metastatic prostate cancer: 1. integrating liquid biopsies and genomic insights into clinical practice to enhance treatment; and 2. developing strategies for de-escalating treatments. As principal investigator, I lead several investigator-initiated and industry-sponsored trials, including serving as the central PI for the Apa-Enza short trial (shortened treatment with apalutamide/enzalutamide in low-volume metastatic castration-sensitive prostate cancer), that is running as an investigator-initiated trial in 28 hospitals in The Netherlands. In addition, I oversee translational research within multiple ongoing studies, supported by a team of two dedicated PhD candidates. Together, we aim to bridge the gap between laboratory discoveries and practical, patient-centered prostate cancer care – through precision therapies and de-escalation strategies. 

2012-2016 PhD student, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
Obtained PhD on the clinical relevance of liquid biopsies in solid cancers

2017-2022 Internal Medicine and Medical Oncology Training at Havenziekenhuis,
Maasstad and Erasmus MC, Rotterdam, The Netherlands

2023 Institute of Cancer Research, London, UK 
Treating advanced prostate cancer patients and performing translational
research (head Prof de Bono)

2024 Erasmus MC Cancer Institute
Prostate Cancer Lead 

Selection of most important publications as first or last author:

“Elucidating acquired PARP inhibitor resistance in advanced prostate cancer”
Cancer Cell. 2024 
https://doi.org/10.1016/j.ccell.2024.10.015

“RNASEH2B loss and PARP inhibition in advanced prostate cancer”
J Clin Invest. 2024
https://doi.org/10.1172/jci178278

“A review of trials investigating ctDNA-guided adjuvant treatment of solid tumor: The importance of trial design”
Eur J Cancer. 2024
https://doi.org/10.1016/j.ejca.2024.114159

“PARP inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues”
Eur Urol 2023
https://doi.org/10.1016/j.eururo.2023.03.038

“Circulating tumour cells to drive the use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer”
ESMO Open. 2022
https://doi.org/10.1016/j.esmoop.2022.100416

All publications

Beije N - Search Results - PubMed

2018 Molecular Medicine School Thesis of the Year Award
2021 ASCO Merit Award
2025 ZonMW Veni